Kadcyla 160 Mg Injection
Kadcyla 160 MG Description
Kadcyla injection contains ado-trastuzumab emtansine, a prescription medication for treating HER2-positive breast cancer. This drug combines trastuzumab, an antibody targeting HER2 receptors, with emtansine, a chemotherapy agent that destroys cancer cells. Kadcyla injection is indicated for both early and advanced stages of breast cancer, particularly in cases where the disease recurs within six months following chemotherapy.
Kadcyla injection may cause side effects like nausea, vomiting, diarrhoea, and hair loss. Tell your doctor right away if you experience any allergic reactions or unusual bleeding. Kadcyla injection typically does not harm your kidneys. In rare cases, you might react to the infusion. Always talk to your healthcare provider for personalized medical advice.
Product Summary
Offer Price | ₹224246.00 |
You Save | ₹30579.00 (12% on MRP) |
Contains | Ado-Trastuzumab Emtansine(160.0 Mg) |
Uses | Breast cancers |
Side effects | Thrombocytopenia, anaemia, peripheral neuropathy, headache, and epistaxis (nosebleed) |
Therapy | ANTI-NEOPLASTIC |
Uses of Kadcyla 160 MG
Contraindications of Kadcyla 160 MG
Side effects of Kadcyla 160 MG
- Thrombocytopenia
- Anaemia
- Peripheral neuropathy
- Headache
- Epistaxis (nosebleed)
- Cough
- Dyspnoea
- Stomatitis
- Diarrhoea
- Vomiting
- Nausea
- Constipation
- Dry mouth
- Abdominal pain
- Rash
- Pruritus
- Alopecia
- Nail disorder
- Musculoskeletal pain
- Arthralgia
- Myalgia
- Fatigue
- Pyrexia
- Asthenia
Precautions and Warnings of Kadcyla 160 MG
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
- You have kidney disease, have undergone a kidney transplant, or have any history of liver disease.
- You are taking anticoagulants or antiplatelet medicines, such as warfarin or heparin.
- You have a history of thrombocytopenia (low platelet count) or are experiencing any signs of unusual bleeding or bruising.
- You have or have had heart conditions such as congestive heart failure, arrhythmias, or a history of myocardial infarction.
- You have a low left ventricular ejection fraction (LVEF) or heart-related symptoms, such as shortness of breath or chest pain.
- You are experiencing symptoms of peripheral neuropathy, such as numbness, tingling, or weakness in your extremities.
- You have experienced any infusion-related reactions or severe allergic reactions to trastuzumab or similar medicines in the past.
- You have a history of lung disease, interstitial lung disease, or pneumonitis.
- You are experiencing symptoms like persistent cough, fatigue, or difficulty breathing.
- You are undergoing or planning to undergo concurrent radiation therapy.
- You are pregnant, planning to become pregnant, or breastfeeding.
- You have any signs of liver dysfunction, such as yellowing of the skin or eyes, dark urine, or unusual fatigue.
- You are on any other medications or supplements, including herbal products, that could interact with trastuzumab emtansine.
- You have a history of hypersensitivity or anaphylactic reactions to medications.
- You experience any injection-site reactions, including pain, redness, or swelling during or after administration.
Directions for Use of Kadcyla 160 MG
Storage and disposal of Kadcyla 160 MG
Dosage of Kadcyla 160 MG
Overdose
Missed a Dose
Mode of Action of Kadcyla 160 MG
How Does It Work?
Interactions of Kadcyla 160 MG
Interactions with other medicines
Content Details
![doctor](https://seo-cdn.pharmeasy.in/production/5a2917e2-4b5c-482d-a199-354b37730211.webp?dim=96x96&q=75)
Ravindra Ghongade
B. Pharm
![doctor](https://seo-cdn.pharmeasy.in/production/3e51d4ee-3092-4b27-a6c9-b73fd1d44f9f.jpg?dim=96x96&q=75)
Dr. Nikita Toshi
BDS (Bachelor of Dental Surgery)
References
- Herceptin 150mg Powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- Herceptin 150mg Powder for concentrate for solution for infusion - Patient Information Leaflet (PIL) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- Kadcyla 100 mg Powder for Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Medicines.org.uk. 2025 [cited 6 January 2025]
- https://www.medicines.org.uk/emc/files/pil.9537.pdf
Other Products from this Brand
Health Articles
Top-Tests we cover:
Top-Selling Healthcare Products:
Top-Selling Medicines:
Top-Searched Medicines: